| 17903364 |
Wang XM, Chen DF: [Effects of rosiglitazone on Kruppul-like factor 6 (KLF6) signaling in the livers of rats with nonalcoholic fatty liver fibrosis]. Zhonghua Gan Zang Bing Za Zhi. 2007 Sep;15(9):649-53.
OBJECTIVE: To study the effects of rosiglitazone on Kruppule-like factor 6 (KLF6) and its target gene TGFa1 during the development of nonalcoholic fatty liver fibrosis. METHOD: Thirty-six Wistar rats were divided into three groups: a control group, a high fat model group and an intervention group. Their blood serum TG, FFA, AST, ALT, HA, LN and CIV were measured. Hepatic expressions of KLF6, TGFbeta1 and alpha-SMA were detected by RT-PCR and immunohistochemistry. The pathological features and the degree of liver fibrosis before and after the rosiglitazone intervention were also studied. RESULTS: The contents of TG, FFA, AST, ALT, HA, LN and CIV, the expression of KLF6, TGFbeta1 and alpha-SMA mRNA, and the degree (score) of liver fibrosis at the 24th week in the model group were significantly higher than those in the control group (P <0.01) but they were lower in the rosiglitazone intervention group (P <0.05). The protein expression of a-SMA was also lower in the intervention group compared with that of the model group. CONCLUSION: Rosiglitazone, to a certain extent, can inhibit KLF6-TGFalpha1 signal transduction by inducing expression of PPAR-gamma, and then inhibit the activation of hepatic stellate cells and minimize hepatic fibrosis. |
5(0,0,0,5) |